Evan M. Lazerowitz

Goldberg Weprin Finkel Goldstein LLP

FDA Delays Critical Decision on Generic Drug Labeling and Scope of Potential Tort Liability Regulations
Friday, July 31, 2015
The current regulations of the Food and Drug Administration (FDA) impose different requirements upon brand-name and generic drug manufacturers when it comes to changes in labeling to reflect newly discovered adverse effects and other drug safety ...